Emphasys Medical is a biotechnology company that is pioneering therapeutic devices for emphysema and other breathing disorders. Its slogan, "Pioneering therapeutic devices for emphysema and other breathing disorders, providing advanced treatment and healing solutions," reflects the company's core mission. The company's flagship product, the Zephyr Endobronchial Valve system, is designed to prevent air from entering the lungs through an opening, thereby reducing or stopping airflow to promote tissue healing.
Founded in 2000, Emphasys Medical is headquartered in Redwood City, California. The company operates within the biotechnology and health care industries, focusing on creating therapeutic devices for respiratory conditions.
Emphasys Medical's last investment was an $18.70M Series E investment on 27 July 2006. The investment was made by Cargill Ventures and Trellis Health Ventures, indicating confidence in the company's innovative approach to tackling respiratory disorders.
